Operational highlights and financial results for the period ended september 30, 2021

New york, nov. 23, 2021 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the first quarter ended september 30, 2021.
MESO Ratings Summary
MESO Quant Ranking